NOVACYT S.A. (NCYT) — Interim Results

Investor webinar replay

Replay transcript excerpt

Good afternoon, and welcome to the NOVACYT Interim Results Investor Presentation. Throughout this recorded presentation, investors will be in listen only mode. Questions are encouraged and can be submitted at any time by the Q and A tab situated in the right hand corner of your screen. Just simply type in your questions and press send. The company may not be in a position to answer every question it receives in the meeting itself. However, the company will review all questions submitted today and publish responses where it's appropriate to do so. Before we begin, I'd like to submit the following poll. And for the benefit of those joining us from France, I'd now like to hand you over to James McCarthy. Good afternoon. Thank you, Alexandra. Good afternoon, everybody. Welcome to the NOVACYT half year results. I should just start by the showing the disclaimer, and I'll just take that as read by everybody before we proceed. Okay. So my name is James McCarthy. I'm the acting CEO of NOVACYT. It happened since November last year. Prior to that, I had an almost two years as the CEO of the group. Delighted to be joined by, Steve Gibson, who's the finance director, and Lynn Reese, who's recently joined us from the Eugene acquisition. So perhaps if I ask those two gentlemen to introduce themselves before we proceed. Perfect. And good afternoon, everyone. Steve Gibson, group finance director. I've been with NOVACYT for around six and a half years. And prior to that, I spent around twelve years at a blue chip IT company working a variety of different commercial finance roles. Luke? Thank you, Steven. Good afternoon, everyone. Real pleasure to be able to, present to you today. My name is Lynn. I'm the, ex CEO of YourGene Health, and I've been in this diagnostic market space for abo...